On the contrary, specifically related to hormone receptor negative BC, a higher infiltration of FOXP3+ Tregs in the stromal site was associated with poor prognosis in patients treated with anti-Her2 therapy, although no significant difference was found when it came to the intratumoral site [42]. Here, ERBB2 is linked to breast cancer.